reparixin: Clinical Trials

13 trials of reparixin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 4 terminated, 1 recruiting, 1 withdrawn. 10 Phase 2, 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 210Completed 5, Terminated 3, Recruiting 1, Withdrawn 1
Phase 35Completed 3, Terminated 2

Follow reparixin: new trials by email Literature Review of reparixin trials Research Report on reparixin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
reparixin - Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF)
Phase 2RecruitingIcahn School of Medicine at Mount Sinai102023-07-242026-05-06
Add-on Reparixin in Adult Patients With ARDS
Reparixin 600mg, Matching Placebo - Acute Respiratory Distress Syndrome, Adult
Phase 2CompletedDompé Farmaceutici S.p.A662022-12-062026-05-11
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Reparixin, Placebo - Infectious Pneumonia, Severe COVID-19
Phase 3TerminatedDompé Farmaceutici S.p.A4142022-04-272026-02-24
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer
Reparixin, Placebo - Fatigue, Locally Advanced or Metastatic Breast Cancer
Phase 2WithdrawnDompé Farmaceutici S.p.A2022-04-192024-04-30
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.
Reparixin, Placebo - Pneumonia, Viral
Phase 3CompletedDompé Farmaceutici S.p.A2872021-02-142024-06-13
Reparixin in COVID-19 Pneumonia - Efficacy and Safety
Reparixin, Standard of care - Severe Pneumonia
Phase 2 / Phase 3TerminatedDompé Farmaceutici S.p.A562020-05-052024-01-08
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
paclitaxel, Reparixin, placebo - Metastatic Breast Cancer
Phase 2CompletedDompé Farmaceutici S.p.A1942015-07-292022-09-16
Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation
Reparixin, Control - Ischemia-reperfusion Injury in Liver Transplant, Early Allograft Dysfunction
Phase 2TerminatedDompé Farmaceutici S.p.A402015-03-102025-01-07
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Reparixin, Placebo - Pancreatectomy for Chronic Pancreatitis
Phase 2 / Phase 3CompletedDompé Farmaceutici S.p.A1042014-02-012023-11-02
Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer
Reparixin - Breast Cancer
Phase 2TerminatedDompé Farmaceutici S.p.A202013-02-012021-05-14
Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation
Reparixin, Placebo - Islet Transplantation in Diabetes Mellitus Type 1
Phase 3CompletedDompé Farmaceutici S.p.A512012-10-012024-01-03
Reparixin in Pancreatic Islet Transplantation
Reparixin - Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus
Phase 2CompletedDompé Farmaceutici S.p.A92010-07-282021-03-11
Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
Repertaxin, Placebo - Ischemia-Reperfusion Injury, Lung Transplantation
Phase 2CompletedDompé Farmaceutici S.p.A1142005-05-012024-12-11

Conditions studied

Breast Neoplasms (3)  ·  COVID-19 (3)  ·  Diabetes Mellitus, Type 1 (2)  ·  Pneumonia (2)  ·  Reperfusion Injury (2)  ·  Fatigue (1)  ·  Pneumonia, Viral (1)  ·  Primary Myelofibrosis (1)  ·  Respiratory Distress Syndrome (1)

Sponsors

Dompé Farmaceutici S.p.A (12)  ·  Icahn School of Medicine at Mount Sinai (1)

Countries

United States (10)  ·  Italy (8)  ·  Germany (4)  ·  Canada (2)  ·  Czechia (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belarus (1)  ·  Belgium (1)  ·  Brazil (1)  ·  France (1)  ·  Poland (1)  ·  Russia (1)  ·  Spain (1)

Top investigators

Aaron Gerds, MD, MS (1)  ·  Alberto Zangrillo, MD PhD (1)  ·  Barbara Ludwig, MD (1)  ·  Enrico Minnella, MD (1)  ·  Giovanni Landoni, MD (1)  ·  Giovanni Landoni, MD, PhD (1)  ·  Lorenzo Piemonti, MD (1)  ·  Lorenzo Piemonti, MD PhD (1)

Results publications

PMID 39735417, PMID 40028879, PMID 40318595, PMID 23912763, PMID 28539464, PMID 31924241, PMID 32019854, PMID 33908301, PMID 34476645, PMID 35618953, PMID 37798468, PMID 37972723

NIH funding

2014 (1)